{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:17:57Z","timestamp":1763036277393},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.beha.2007.02.001","type":"journal-article","created":{"date-parts":[[2007,8,18]],"date-time":"2007-08-18T11:16:56Z","timestamp":1187435816000},"page":"455-468","source":"Crossref","is-referenced-by-count":45,"title":["Prognostic markers in chronic lympocytic leukaemia"],"prefix":"10.1016","volume":"20","author":[{"given":"Terry J.","family":"Hamblin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2007.02.001_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","article-title":"A clinical staging system for chronic lymphocytic leukemia","volume":"40","author":"Binet","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.02.001_bib3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukaemia: a meta-analysis of the randomised trials","volume":"91","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.beha.2007.02.001_bib4","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2005-04-1677","article-title":"Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia","volume":"107","author":"Binet","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.02.001_bib7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood.V100.2.635","article-title":"Monoclonal B lymphocytes with the characteristics of \u2018indolent\u2019 chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib8","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2002-03-0892","article-title":"Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10013","article-title":"B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia","volume":"52","author":"Marti","year":"2003","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"10.1016\/j.beha.2007.02.001_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2141.1981.tb07243.x","article-title":"Total tumour mass score (TTM): a new parameter in chronic lymphocyte leukaemia","volume":"49","author":"Jaksic","year":"1981","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.02.001_bib11","first-page":"428","article-title":"Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2007.02.001_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1182\/blood.V100.4.1215.h81602001215_1215_1219","article-title":"The clinical significance of tunor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia","volume":"100","author":"Ferrajoli","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/cncr.10772","article-title":"Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia","volume":"96","author":"Lai","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.02.001_bib14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1365-2141.2003.04118.x","article-title":"Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukemia","volume":"120","author":"Wierda","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.02.001_bib15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood-2005-05-2110","article-title":"Plasma thrombpoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia","volume":"108","author":"Koller","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.1981.tb02681.x","article-title":"Prognostic significance of bone marrow patterns in chronic lymphocytic leukaemia","volume":"47","author":"Rozman","year":"1981","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.02.001_bib17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2141.1986.tb02969.x","article-title":"Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance","volume":"62","author":"Montserrat","year":"1986","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.02.001_bib18","unstructured":"Galton DAG. The natural history of chronic lymphocytic leukaemia. MD thesis. Cambridge University, Cambridge, 1963."},{"key":"10.1016\/j.beha.2007.02.001_bib19","first-page":"1005","article-title":"The pathogenesis of chronic lymphocytic leukaemia","volume":"94","author":"Galton","year":"1966","journal-title":"Canadian Medical Association Journal"},{"key":"10.1016\/j.beha.2007.02.001_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood.V29.4.566.566","article-title":"Chronic lymphocytic leukemia-an accumulative disease of immunologically incompetent lymphocytes","volume":"29","author":"Dameshek","year":"1967","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0145-2126(82)90068-6","article-title":"Purine and pyrimidine activities in acute and chronic lymphocytic leukaemia: relation to cellular proliferative status","volume":"6","author":"Gan","year":"1982","journal-title":"Leukemia Research"},{"key":"10.1016\/j.beha.2007.02.001_bib22","first-page":"47","article-title":"Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia","volume":"6","author":"Orfao","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.02.001_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/cyto.990100612","article-title":"Simultaneous flow cytometric analysis of surface markers and nuclear Ki-67 antigen in leukemia and lymphoma","volume":"10","author":"Drach","year":"1989","journal-title":"Cytometry"},{"key":"10.1016\/j.beha.2007.02.001_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/10428199309148548","article-title":"Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukaemia (CLL)","volume":"10","author":"Del Giglio","year":"1993","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2007.02.001_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2003-04-1345","article-title":"Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations","volume":"103","author":"Damle","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI23409","article-title":"In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells","volume":"115","author":"Messmer","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2007.02.001_bib27","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1002\/1097-0142(19871201)60:11<2712::AID-CNCR2820601122>3.0.CO;2-1","article-title":"Prognostic value of lymphocyte doubling time in chronic lymphocytic leukemia","volume":"60","author":"Molica","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.02.001_bib28","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high\u00a0risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.leu.2402780","article-title":"Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL","volume":"17","author":"Magnac","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.02.001_bib30","first-page":"359","article-title":"Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages","volume":"30","author":"Montserrat","year":"1988","journal-title":"Nouvelle revue fran\u00e7aise d'h\u00e9matologie"},{"key":"10.1016\/j.beha.2007.02.001_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.1990.tb07835.x","article-title":"Natural history of stage A chronic lymphocytic leukaemia untreated patients","volume":"76","author":"French Cooperative Group on Chronic Lymphocytic Leukaemia","year":"1990","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.02.001_bib32","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/14728222.9.6.1165","article-title":"Functional and prognostic role of ZAP-70 in CLL","volume":"9","author":"Hamblin","year":"2005","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.beha.2007.02.001_bib33","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.V87.7.2615.bloodjournal8772615","article-title":"Caligaris-Cappio fb: Chronic lymphocytic leukemia: a malignancy of anti-self B cells","volume":"87","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib34","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1073\/pnas.86.15.5913","article-title":"Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia","volume":"86","author":"Kipps","year":"1989","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2007.02.001_bib35","first-page":"646","article-title":"Preferential rearrangement of developmentally regulated immunoglobulin VH1 genes in human B-lineage leukaemias","volume":"5","author":"Deane","year":"1991","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.02.001_bib36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0167-5699(94)90009-4","article-title":"The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire","volume":"15","author":"Schroeder","year":"1994","journal-title":"Immunology Today"},{"key":"10.1016\/j.beha.2007.02.001_bib37","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors","volume":"102","author":"Fais","year":"1998","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2007.02.001_bib38","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood.V89.11.4153","article-title":"Differential rates of somatic hypermutation in VH genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities","volume":"89","author":"Oscier","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib39","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJM199009133231105","article-title":"Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities","volume":"323","author":"Juliusson","year":"1990","journal-title":"The New England Journal of Medicine"},{"issue":"supplement 1","key":"10.1016\/j.beha.2007.02.001_bib40","first-page":"515a","article-title":"In chronic lymphocytic leukemias germline configuration of immunoglobulin heavy chain genes is associated with a more aggressive form of the disease","volume":"92","author":"Hamblin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib41","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib42","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood.V96.1.377","article-title":"Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia","volume":"95","author":"Maloum","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib44","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1046\/j.1365-2141.2001.03149.x","article-title":"Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia","volume":"115","author":"Jelinek","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.02.001_bib45","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.leu.2402537","article-title":"Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course","volume":"16","author":"Stilgenbauer","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.02.001_bib46","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1182\/blood-2003-05-1549","article-title":"The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status","volume":"103","author":"Ritgen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00277-002-0476-1","article-title":"Chronic lymphocytic leukaemia: one disease or two?","volume":"81","author":"Hamblin","year":"2002","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.beha.2007.02.001_bib48","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood.V99.6.2262","article-title":"Somatically mutated IgVH3-21 genes characterize a new subset of chronic lymphocytic leukemia","volume":"99","author":"Tobin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib49","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2002-11-3485","article-title":"Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted V lambda 2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope","volume":"101","author":"Tobin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.20040544","article-title":"Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia","volume":"200","author":"Messmer","year":"2004","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2007.02.001_bib51","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood.V95.7.2455","article-title":"Immunoglobulin V genes and CD38 expression in CLL","volume":"95","author":"Hamblin","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib52","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","article-title":"CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease","volume":"99","author":"Hamblin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib53","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood-2006-01-013003","article-title":"In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia","volume":"108","author":"Deaglio","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib54","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"issue":"supplement 1","key":"10.1016\/j.beha.2007.02.001_bib55","first-page":"35","article-title":"CD38 as a prognostic indicator in B-CLL","volume":"42","author":"Thornton","year":"2001","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2007.02.001_bib56","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","article-title":"The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression","volume":"101","author":"Ghia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.leu.2404133","article-title":"CD38+ chronic lymphocytic leukaemia cells co-express high levels\u00a0of ZAP-70 and are functionally distinct from their CD38- counter-parts","volume":"20","author":"Pepper","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.02.001_bib58","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells","volume":"194","author":"Klein","year":"2001","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2007.02.001_bib59","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosenwald","year":"2001","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2007.02.001_bib60","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","article-title":"Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia","volume":"100","author":"Chen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib61","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2002-06-1822","article-title":"Differential signaling via surface IgM is associated with VH gene\u00a0mutational status and CD38 expression in chronic lymphocytic leukemia","volume":"101","author":"Lanham","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib62","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1182\/blood.V100.9.3068","article-title":"The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signalling for apoptosis","volume":"100","author":"Cragg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib63","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2004-05-1715","article-title":"ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia","volume":"105","author":"Chen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib64","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2006-03-011759","article-title":"ZAP-70 enhances B-cell receptor signaling in spite of absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B-cells","volume":"109","author":"Gobessi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib65","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1182\/blood-2005-03-1099","article-title":"ZAP-70 is a novel conditional Heat shock protein 90 (Hsp90)-client protein: Inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis and impaired signaling in chronic lymphocytic leukemia","volume":"106","author":"Castro","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib66","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib67","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.02.001_bib68","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","article-title":"ZAP-70 expression by flow cytometry is a good prognostic marker in CLL and a potential surrogate for immunoglobulin VH gene mutations","volume":"363","author":"Orchard","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2007.02.001_bib69","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.02.001_bib70","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.2005.03.7184","article-title":"Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia","volume":"24","author":"Krober","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.02.001_bib71","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/cyto.b.20137","article-title":"ZAP-70 in CLL: towards standardization of a biomarker for patient management: history of clinical cytometry special issue","volume":"70B","author":"Marti","year":"2006","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"10.1016\/j.beha.2007.02.001_bib72","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/cyto.b.20135","article-title":"An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression un chronic lymphocytic leukemia","volume":"70B","author":"Shankey","year":"2006","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"10.1016\/j.beha.2007.02.001_bib73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/cyto.b.20121","article-title":"ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis","volume":"70B","author":"Best","year":"2006","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"10.1016\/j.beha.2007.02.001_bib74","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cyto.b.20132","article-title":"Evaluation ofZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process","volume":"70B","author":"Letestu","year":"2006","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"10.1016\/j.beha.2007.02.001_bib75","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/cyto.b.20127","article-title":"ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T\/NK cells) controls and correlation with IgVH mutations","volume":"70B","author":"Zucchetto","year":"2006","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"10.1016\/j.beha.2007.02.001_bib76","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cyto.b.20136","article-title":"A standardized ZAP-70 assay \u2013 lessons learned from the trenches","volume":"70B","author":"Shults","year":"2006","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"10.1016\/j.beha.2007.02.001_bib77","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/cyto.b.20128","article-title":"Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia","volume":"70B","author":"Sheridan","year":"2006","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"10.1016\/j.beha.2007.02.001_bib78","first-page":"S43","article-title":"ZAP-70 expression remains stable during the course of chronic lymphocytic leukemia","volume":"46","author":"Villamor","year":"2005","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2007.02.001_bib79","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.02.001_bib80","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-4608(87)90091-4","article-title":"Chromosome abnormalities involving band 13q14 in hematologic malignancies","volume":"24","author":"Fitchett","year":"1987","journal-title":"Cancer Genetics and Cytogenetics"},{"key":"10.1016\/j.beha.2007.02.001_bib81","doi-asserted-by":"crossref","first-page":"11755","DOI":"10.1073\/pnas.0404432101","article-title":"MicroRNA profiling reveals distinct signatures in B-cell chronic lymphocytic leukemia","volume":"101","author":"Calin","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2007.02.001_bib82","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2007.02.001_bib83","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1046\/j.1365-2141.1997.3263141.x","article-title":"Prognostic factors in stage A chronic lymphocytic leukaemia; the importance of atypical lymphocyte morphology and abnormal karyotype for disease progression in stage A CLL","volume":"98","author":"Oscier","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.02.001_bib84","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood.V89.7.2516","article-title":"11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterised by extensive nodal involvement and inferior prognosis","volume":"89","author":"Dohner","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib85","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2001-11-0066","article-title":"Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia","volume":"100","author":"Lin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib86","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2004-11-4516","article-title":"Mutations in the ATM gene lead to impaired overall and treatment-free\u00a0survival that is independent of IGVH mutation status in patients with B-CLL","volume":"106","author":"Austen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib87","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib88","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","article-title":"Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors","volume":"100","author":"Oscier","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib89","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib90","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2006.06.9492","article-title":"Prospective evolution during long-term follow-up of patients with untreated early stage chronic lymphocytic leukemia","volume":"24","author":"Shanafelt","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.02.001_bib91","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2403242","article-title":"Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis","volume":"18","author":"Cuneo","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.02.001_bib92","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high risk features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.02.001_bib93","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/cncr.21535","article-title":"The addition of rituximab improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia","volume":"104","author":"Del Poeta","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.02.001_bib94","doi-asserted-by":"crossref","first-page":"212a","DOI":"10.1182\/blood.V106.11.715.715","article-title":"17p deletion predicts for overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG","volume":"106","author":"Stilgenbauer","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib95","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib96","doi-asserted-by":"crossref","first-page":"594a","DOI":"10.1182\/blood.V106.11.2099.2099","article-title":"Prognostic factors in the UK LRF CLL4 trial","volume":"106","author":"Oscier","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.02.001_bib97","first-page":"S46","article-title":"Can we predict which patients with early stage CLL will progress and require treatment?","volume":"46","author":"Hamblin","year":"2005","journal-title":"Leukemia & Lymphoma"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T23:58:00Z","timestamp":1587859080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692607000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1521692607000175"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2007.02.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}